title: Reprint of: Allogeneic hematopoietic cell transplantation for acute myeloid leukemia.
abstract: Allogeneic stem cell transplantation is an increasingly important treatment option in the management of adult acute myeloid leukemia (AML). The major causes of treatment failure remain disease relapse and treatment toxicity. In this review, Dr Vyas presents an overview of important recent data defining molecular factors associated with treatment failure in AML. He also identifies the emerging importance of leukemia stem cell biology in determining both response to therapy and relapse risk in AML. Dr Appelbaum discusses advances in the design and delivery of both myeloablative and reduced-intensity conditioning regimens, highlighting novel strategies with the potential to improve outcome. Dr Craddock discusses the development of both novel conditioning regimens and post-transplantation strategies aimed at reducing the risk of disease relapse.
authors.affiliation: Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
authors.forename: Paresh
authors.initials: P
authors.lastname: Vyas
authors.affiliation: Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington.
authors.forename: Frederick R
authors.initials: FR
authors.lastname: Appelbaum
authors.affiliation: Queen Elizabeth Hospital, Birmingham, United Kingdom. Electronic address: charles.craddock@uhb.nhs.uk.
authors.forename: Charles
authors.initials: C
authors.lastname: Craddock
keywords: Acute myeloid leukemia; Conditioning regimen; Disease relapse; Graft-versus-leukemia; Leukemic stem/progenitor cell; Reduced-intensity conditioning